Albuterol

In a small trial of young men doing resistance training, oral salbutamol increased mean sprint power more than placebo; peak power and strength improved similarly. These results concern oral exposure and do not establish the same effect for inhaled asthma treatment.^[1]

• Oral experimental exposure cannot be substituted for inhaled bronchodilator dosing or long-term clinical safety.
• Abstract-checked; no qualified clinical review.

CYTOMEL labeling states that sympathomimetics may increase the effects of thyroid hormone or sympathomimetics; coronary insufficiency is a particular concern in coronary artery disease.^[2]

• A drug-class label warning for oral liothyronine; not a clinical trial of each selected pair.
• Caffeine, phenylpiracetam and all products tagged “stimulant” cannot automatically be treated as equivalent.

FDA warns that people who “stack” steroid-like bodybuilding products with other products, including stimulants, may be at greater risk for serious and life-threatening reactions. This broad warning does not establish the effect or severity of an individual compound pair.^[3]

• This evidence does not establish the magnitude or frequency of harm from the selected combination.

In hemodialysis patients, intravenous insulin with glucose plus nebulized albuterol lowered potassium more than either treatment alone; the same study reports that albuterol blunted, rather than added to, insulin's glucose-lowering (hypoglycemic) effect. Application to the rapid- or long-acting insulin records is a formulation and route extrapolation.^[4]

• The inspected abstract does not identify an insulin analogue; this result cannot be presented as an exact study of lispro or glargine.
• Does not establish a quantitative clenbuterol interaction.
• This 1990 study describes a deliberate, supervised hyperkalemia treatment, not an adverse interaction; the potassium-lowering axis is distinct from the separate glucose-lowering-effect axis now also documented in HUMALOG's own label (see ix-insulin-albuterol-glycemic).

HUMALOG's drug-interaction table names albuterol as an example of a sympathomimetic agent that may decrease HUMALOG's blood-glucose-lowering effect, and recommends dose adjustment and increased glucose monitoring when these are coadministered.^[5]

• Albuterol is named as one example within a long generic drug-class list in the label, not an isolated albuterol trial.
• Describes a glucose-lowering-effect axis distinct from the potassium-lowering effect covered by ix-insulin-albuterol-potassium.